TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
$HIMS · Hims & Hers HUGE Acquisition News! | $HIMS
now playing · $HIMS
$HIMS···neutral· mediumtravis hoium
Travis Holm analyzes HIMS $1.15B Eucalyptus acquisition: balance sheet risk vs international platform upside
The Eucalyptus acquisition leverages up HIMS' balance sheet using cash from last year's convertible notes, removing the pristine balance sheet cushion amid the Novo Nordisk lawsui…
$EUCALYPTUSneutral· mediumtravis hoium
Eucalyptus acquired by HIMS for $1.15B to expand into Australia, Japan, UK, Germany, Canada
Eucalyptus brings $450M revenue run-rate and established presence in Australia, Japan, UK, Germany, and Canada, serving as the vehicle for HIMS' international aggregator strategy.…
$ZAVAneutral· lowtravis hoium
Zava acquisition last year part of HIMS international rollout before Eucalyptus deal
Zava was HIMS' first international acquisition, establishing a foothold in Europe before the larger Eucalyptus deal expanded the footprint further.
$NVO···bearish· mediumtravis hoium
Novo Nordisk lawsuit creates downside risk for HIMS if GLP-1 compounding challenged
The ongoing lawsuit with Novo Nordisk poses material downside risk — if it goes poorly, it could be costly and hurt HIMS' growth and margins, especially as the company leverages u…